Ciara Conduit (@ciaraconduit) 's Twitter Profile
Ciara Conduit

@ciaraconduit

Medical Oncologist @TasmaniaHealth, #testicularcancer Research Fellow WEHI @gibbs_lab. Love dogs, cycling (she/her)

ID: 703131595960549378

calendar_today26-02-2016 08:16:50

318 Tweet

446 Followers

656 Following

Marc Diocera (@marcdiocera) 's Twitter Profile Photo

So lucky & proud of this work! | Full article: What is ethically required to adapt to intellectual disability in #cancer care? A case study of #testicularcancer management tandfonline.com/doi/full/10.31… | Peter Mac Cancer Centre GU Cast | Urology podcast!

Laurence Albiges (@albigesl) 's Twitter Profile Photo

Pleased to share The Lancet Oncology LENVA-PEMBRO across RCC variant histologies: papillary RCC, unclRCC and chromophobe RCC … interim ESMO - Eur. Oncology #ESMO22 and final Chung-Han Lee 李宗翰, MD/PhD ASCO #ASCO23 full text: authors.elsevier.com/a/1hP1c5EIIgLp… Thanks to all who change rareRCC pts Tx!

Pleased to share <a href="/TheLancetOncol/">The Lancet Oncology</a> LENVA-PEMBRO  across RCC variant histologies: papillary RCC, unclRCC and chromophobe RCC … interim <a href="/myESMO/">ESMO - Eur. Oncology</a> #ESMO22 and  final <a href="/ChungHanLee3/">Chung-Han Lee 李宗翰, MD/PhD</a>  <a href="/ASCO/">ASCO</a> #ASCO23 

full text: authors.elsevier.com/a/1hP1c5EIIgLp… 
Thanks to all who change 
 rareRCC pts Tx!
Jon Lim, MRCP PhD (@drjonlim) 's Twitter Profile Photo

#ESMO23 #YObrunch session 1️⃣ - super insightful talk & educational discussion around #LGBTQIA cancer care by @DrAllyCat; something that’s definitely still lacking in our oncology training to date. Strongly recommend #YoungOncologists to watch this #ondemand, if you missed this.

#ESMO23 #YObrunch session 1️⃣ - super insightful talk &amp; educational discussion around #LGBTQIA cancer care by @DrAllyCat; something that’s definitely still lacking in our oncology training to date.

Strongly recommend #YoungOncologists to watch this #ondemand, if you missed this.
Sumanta K. Pal, MD, FASCO (@montypal) 's Twitter Profile Photo

Eloquent discussion from Andrea Apolo, M.D. National Cancer Institute synthesizing data from #EV302 & #CM901. Loved the fact that she offered a strong, definitive opinion on the "winner" in the battle between these options. Also (not shown) great outline of remaining questions - what comes after EVP?

Eloquent discussion from <a href="/apolo_andrea/">Andrea Apolo, M.D.</a> <a href="/theNCI/">National Cancer Institute</a> synthesizing data from #EV302 &amp; #CM901. Loved the fact that she offered a strong, definitive opinion on the "winner" in the battle between these options. Also (not shown) great outline of remaining questions - what comes after EVP?
Ciara Conduit (@ciaraconduit) 's Twitter Profile Photo

Brilliant work from a brilliant trainee! Nice to see her hard work come to fruition and hopefully we’ll see improvements for this population when EV/pembro becomes available. #bladdercancer ESMO - Eur. Oncology #ESMOAsia23

Tom Powles (@tompowles1) 's Twitter Profile Photo

Serial ctDNA testing from IMVIGOR11 (post cystectomy in muscle invasive bladder cancer) show that ctDNA-ve patients (n=171) with a minimum of 12months follow up have 10% relapse rates and almost no deaths #EAU24. Do we need to give adjuvant therapy to those as such low risk?

Serial ctDNA testing from IMVIGOR11 (post cystectomy in muscle invasive bladder cancer)  show that ctDNA-ve patients  (n=171) with a minimum of 12months follow up have 10% relapse rates and almost no deaths #EAU24. Do we need to give adjuvant therapy to those as such low risk?
Michael Hofman (@drmhofman) 's Twitter Profile Photo

ENZA-P in The Lancet Oncology Lu-177 PSMA-617 + enzalutamide vs. enza alone: ● ↑PFS: 13.0 vs 7.8, hazard radio 0.43 ● PSA90 response 78% vs 37% ● PSA50 response 93% vs. 68% ● no additional side effects Incredible work from Louise Emmett Ian Davis & ANZUP team

ENZA-P in <a href="/TheLancetOncol/">The Lancet Oncology</a> 

Lu-177 PSMA-617 + enzalutamide vs. enza alone: 

● ↑PFS: 13.0 vs 7.8, hazard radio 0.43
● PSA90 response 78% vs 37%
● PSA50 response 93% vs. 68%
● no additional side effects

Incredible work from <a href="/drlouiseemmett/">Louise Emmett</a> <a href="/Prof_IanD/">Ian Davis</a> &amp; <a href="/ANZUPtrials/">ANZUP</a> team
Prof. Haryana Dhillon (@hagsie) 's Twitter Profile Photo

Congratulations to Ciara Conduit Ben Tran & team on completing this single arm phase II clinical trial of pseudoephedrine for #ejaculatorydysfunction after #RPLND #TesticularCancer #OzOnc ANZUP @pocog1 @SurvOnc #SuppOnc #Fertility COSA bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.11…